REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Abstract Background Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexp...

Full description

Bibliographic Details
Main Authors: Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, Giovanni Grignani, Antoine Italiano, Javier Lavernia, Ana Vallejo, Paolo Dei Tos, Francois Le Loarer, Ricardo Gonzalez-Campora, Rafael Ramos, Diana Hernández-Jover, Antonio Gutierrez, Cesar Serrano, Maria Monteagudo, Rocio Letón, Mercedes Robledo, David S. Moura, Marta Martin-Ruiz, Jose A. López-Guerrero, Julia Cruz, Antonio Fernandez-Serra, Jean-Yves Blay, Elena Fumagalli, Virginia Martinez-Marin
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Molecular Cancer
Subjects:
Wild type GIST
SDH: Regorafenib
Biomarker
Clinical trial
Online Access:https://doi.org/10.1186/s12943-023-01832-9

Internet

https://doi.org/10.1186/s12943-023-01832-9

Similar Items